Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 6, pp 10–13 | Cite as

ASCO Spotlight Falls on Targeted Therapies

Emerging Technology


Sorafenib Metastatic Breast Cancer Sunitinib Lapatinib Herceptin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bayer, Onyx Pharmaceuticals. Sorafenib (BAY 43-9006) doubles progression-free survival in phase III kidney cancer trial. Media release: 14 May 2005Google Scholar
  2. 2.
    Onyx Pharmaceuticals. Bayer and Onyx unblind patients in ongoing sorafenib phase III clinical trial in advanced renal cell carcinoma. Media release: 18 Apr 2005Google Scholar
  3. 3.
    European Pharmaceuticals. Bayer: Feedback from LB pre-ASCO dinner with sorafenib primary investigator. New York: Lehman Brothers Equity Research, 2005Google Scholar
  4. 4.
    European Pharmaceuticals. Major Pharmaceuticals: ASCO update — day 1 and 2 review. New York: Lehman Brothers Equity Research, 2005Google Scholar
  5. 5.
    Pfizer. New data show Pfizer’s SUTENT/SU11248 (sunitinib malate) extends overall survival in Gleevec-resistant GIST. Media release: 17 May 2005Google Scholar
  6. 6.
    Novartis. First results from PTK/ZK CONFIRM 1 trial presented at American Society of Clinical Oncology show positive drug effects in advanced colorectal cancer. Media release: 13 May 2005Google Scholar
  7. 7.
    Novartis PTK/ZK 787 data presented at ASCO; survival analysis pending. Pink Sheet 2005; 67 (22): 20Google Scholar
  8. 8.
    GlaxoSmithKline. GlaxoSmithKline issues update on lapatinib: new clinical data and regulatory filing plans. Media release: 15 May 2005Google Scholar
  9. 9.
    GSK lapatinib breast cancer development shifts to front-line setting. Pink Sheet 2005; 67 (21): 13Google Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations